Beractant

Drug Overview

In the clinical specialty of Pulmonology, particularly within neonatal intensive care, the transition from the womb to independent breathing is the most critical physiological milestone. Beractant is a life-saving medication used to facilitate this transition in premature infants. It belongs to the drug class known as a Pulmonary Surfactant. This specialized substance is essential for maintaining lung stability; without it, the tiny air sacs in a newborn’s lungs would collapse with every breath, leading to exhaustion and respiratory failure.

Beractant is a natural bovine lung extract, carefully processed to provide a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins. For families and clinicians dealing with the high-stakes environment of the Neonatal Intensive Care Unit (NICU), beractant represents a foundational Targeted Therapy that allows underdeveloped lungs to function while the infant continues to grow.

• Generic Name: Beractant
• US Brand Names: Survanta
• Route of Administration: Intratracheal Instillation (directly into the windpipe)
• FDA Approval Status: Fully FDA-approved for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.

What Is It and How Does It Work? (Mechanism of Action)

To understand beractant at the molecular level, one must understand the physics of the lung’s air-liquid interface. The lungs are composed of millions of tiny sacs called alveoli. These sacs are naturally lined with a thin layer of water. Due to surface tension, the water molecules want to pull toward each other, which creates a collapsing force on the alveoli.

In a full-term infant, the body produces a natural surfactant that breaks this surface tension. However, premature infants often lack this substance. Beractant works through a specific physiological mechanism:

1. Lowering Surface Tension: Once instilled into the trachea, beractant spreads rapidly as a thin film across the internal surface of the alveoli.
2. Molecular Displacement: The phospholipids in beractant (primarily dipalmitoylphosphatidylcholine) align themselves at the air-liquid interface. They effectively “push” the water molecules apart.
3. Alveolar Stabilization: By significantly reducing surface tension, beractant prevents the alveoli from completely collapsing during exhalation (end-expiration).

Physiologically, this increases “lung compliance,” meaning the lungs become easier to inflate with less pressure. It reduces the “work of breathing” for the infant and improves gas exchange, allowing oxygen to enter the bloodstream and carbon dioxide to exit more efficiently. This prevents the progressive lung injury caused by the mechanical friction of air sacs constantly opening and snapping shut.

FDA-Approved Clinical Indications

Beractant is utilized strictly within the neonatal population to manage acute restrictive lung disorders.

• Primary Indication: Prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) in premature infants.
• Other Approved & Off-Label Uses:
  • Meconium Aspiration Syndrome (MAS): Used off-label to overcome surfactant inactivation caused by inhaled fetal waste.
  • Neonatal Pneumonia: Occasionally used off-label to improve oxygenation in severe infection cases.
  • Congenital Diaphragmatic Hernia: Used in some protocols to support underdeveloped lung tissue.

Primary Pulmonology Indications:

• Improvement of Ventilation: By stabilizing the air sacs, beractant allows for lower ventilator pressures, reducing the risk of “barotrauma” (pressure-induced lung damage).
• Reduction of Exacerbations: Early “prophylactic” use in very low-birth-weight infants prevents the development of severe RDS.
• Slowing Decline of Lung Function: Proper surfactant management is key in preventing Chronic Lung Disease of Prematurity, also known as Bronchopulmonary Dysplasia (BPD).

Dosage and Administration Protocols

Beractant is administered via an endotracheal tube. Unlike a Metered-Dose Inhaler (MDI) or Dry Powder Inhaler (DPI) used by adults, this is a liquid suspension delivered by a medical team.

Indication	Standard Dose	Frequency
RDS Prevention/Treatment	100 mg of phospholipids/kg birth weight (4 mL/kg)	Up to 4 doses in the first 48 hours of life

Specific Instructions:

• Administration Technique: The dose is usually divided into four “quarters.” The infant is positioned differently for each quarter-dose to ensure the liquid spreads to all lobes of the lung.
• Warming: The vial must be warmed by standing at room temperature for 20 minutes or held in the hand; it should never be artificially heated.
• Suctioning: Clinicians should avoid suctioning the infant’s airway for at least one hour after administration unless signs of airway obstruction occur.
• Monitoring: Continuous monitoring of heart rate and oxygen saturation (SpO2) is mandatory during the procedure.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical data from 2020–2026 continues to reinforce beractant as a gold standard in neonatal Pulmonology. Multi-center randomized trials comparing beractant to other surfactants or placebo have yielded precise numerical data regarding infant survival.

• RDS Severity: Infants treated with beractant show a 40% to 50% reduction in the incidence of severe RDS.
• Mortality Rates: Research indicates that prophylactic use of beractant in infants born before 30 weeks reduces the risk of death due to RDS by approximately 30%.
• Oxygenation Metrics: Clinical trials consistently demonstrate an immediate improvement in the “A-a gradient” (the efficiency of oxygen moving from lungs to blood) within 30 minutes of the first dose.
• BPD Reduction: While it does not eliminate the risk, current research shows that infants receiving early surfactant therapy spend fewer days on mechanical ventilation, which is a major predictor of improved quality of life and reduced long-term lung scarring.

Safety Profile and Side Effects

Black Box Warning: Beractant does not currently have a “Black Box Warning.” However, it is a high-alert medication that can cause rapid changes in lung physiology.

Common Side Effects (>10%):

• Transient Bradycardia (temporary slowing of heart rate during administration)
• Oxygen Desaturation (temporary drop in SpO2 during the procedure)

Serious Adverse Events:

• Endotracheal Tube Blockage: The thick suspension can temporarily clog the breathing tube.
• Pulmonary Hemorrhage: A rare but serious risk, particularly in very premature or low-birth-weight infants.
• Hyperoxia: Because the drug works so quickly, oxygen levels in the blood can rise too fast, potentially damaging the eyes (Retinopathy of Prematurity) if ventilator settings aren’t adjusted immediately.
• Pneumothorax: Rapid changes in lung compliance can lead to a “popped” lung if ventilator pressures are not lowered by the clinician.

Management Strategies:

• Vigilance: Clinicians must be ready to manually ventilate the infant if the tube becomes obstructed.
• Rapid Adjustment: Ventilator settings (PIP and FiO2) must be adjusted “on the fly” as the lungs become more elastic.

Research Areas

Direct Clinical Connections: Current research (2020–2026) is investigating the drug’s role in “surfactant production” pathways. There is a focused effort to understand if beractant can act as a bridge, stimulating the infant’s own Type II alveolar cells to begin natural production sooner.

Generalization: Significant advancements are occurring in Novel Delivery Systems. Research is currently focused on “LISA” (Less Invasive Surfactant Administration), where beractant is delivered through a thin catheter while the infant is on non-invasive CPAP, avoiding the need for a full breathing tube.

Severe Disease & Precision Medicine: Researchers are looking into “Biologic” phenotyping of neonatal lung fluid. By analyzing the proteins in a baby’s lungs, clinicians hope to predict which infants will need a second or third dose of beractant, rather than following a “one size fits all” dosing schedule.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Chest X-ray to confirm the “ground glass” appearance of RDS. Continuous Pulse Oximetry (SpO2) and arterial blood gas (ABG) analysis.
• Organ Function: Continuous monitoring of heart rate and blood pressure is required, as the drug can affect hemodynamics.
• Screening: Review of the mother’s history, including whether antenatal steroids were administered to help mature the baby’s lungs before birth.

Monitoring and Precautions

• Vigilance: NICU teams must monitor for the need for “Step-down” respiratory support (e.g., moving from a ventilator to a CPAP machine) as the beractant takes effect.
• Lifestyle: For premature infants, “lifestyle” management focuses on developmental care—minimizing noise, light, and stress to allow the lungs to heal.
• Vaccination: Infants treated for RDS are high-priority candidates for the Palivizumab (RSV) vaccine series once they reach the appropriate age/season.

Do’s and Don’ts

• DO ensure the infant is stable and the endotracheal tube is in the correct position before dosing.
• DO watch the chest rise carefully; a sudden increase in chest movement means the lungs are becoming more elastic.
• DO keep the infant warm and strictly monitor oxygen levels.
• DON’T suction the infant’s airway immediately after giving the medicine unless the tube is blocked.
• DON’T use beractant if the vial shows signs of excessive foaming or discoloration.
• DON’T ignore a sudden drop in heart rate; pause the procedure and provide ventilatory support.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Beractant is a prescription medication that must be administered only by qualified healthcare professionals in a controlled hospital setting. Always consult with a specialized neonatologist or pulmonologist regarding the care of a newborn. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.